The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain
Abstract
:1. Introduction
2. Diabetes Induced Dementia as the Type 3 Diabetes
3. Glucagon-Like Peptide 1 (GLP1)
4. The Effect of GLP-1 in Type 3 Diabetes: GLP-1 Attenuates Neuroinflammation and Improves Neurogenesis and Insulin Sensitivity in AD
5. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Querfurth, H.W.; LaFerla, F.M. Alzheimer’s disease. N. Engl. J. Med. 2010, 362, 329–344. [Google Scholar] [CrossRef] [PubMed]
- LaFerla, F.M.; Green, K.N. Animal models of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2, a006320. [Google Scholar] [CrossRef] [PubMed]
- Akter, K.; Lanza, E.A.; Martin, S.A.; Myronyuk, N.; Rua, M.; Raffa, R.B. Diabetes mellitus and Alzheimer’s disease: Shared pathology and treatment? Br. J. Clin. Pharmacol. 2011, 71, 365–376. [Google Scholar] [CrossRef] [PubMed]
- Baglietto-Vargas, D.; Shi, J.; Yaeger, D.M.; Ager, R.; LaFerla, F.M. Diabetes and Alzheimer’s disease crosstalk. Neurosci. Biobehav. Rev. 2016, 64, 272–287. [Google Scholar] [CrossRef] [PubMed]
- Mamelak, M. Energy and the Alzheimer brain. Neurosci. Biobehav. Rev. 2017, 75, 297–313. [Google Scholar] [CrossRef] [PubMed]
- Roh, E.; Song, D.K.; Kim, M.S. Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism. Exp. Mol. Med. 2016, 48, e216. [Google Scholar] [CrossRef] [PubMed]
- Roh, E.; Kim, M.S. Brain Regulation of Energy Metabolism. Endocrinol. Metab. 2016, 31, 519–524. [Google Scholar] [CrossRef] [PubMed]
- Attwell, D.; Laughlin, S.B. An energy budget for signaling in the grey matter of the brain. J. Cereb. Blood Flow Metab. 2001, 21, 1133–1145. [Google Scholar] [CrossRef] [PubMed]
- Magistretti, P.J.; Pellerin, L. Metabolic coupling during activation. A cellular view. Adv. Exp. Med. Biol. 1997, 413, 161–166. [Google Scholar] [PubMed]
- Doraiswamy, P.M.; Sperling, R.A.; Coleman, R.E.; Johnson, K.A.; Reiman, E.M.; Davis, M.D.; Grundman, M.; Sabbagh, M.N.; Sadowsky, C.H.; Fleisher, A.S.; et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study. Neurology 2012, 79, 1636–1644. [Google Scholar] [CrossRef] [PubMed]
- Holst, J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007, 87, 1409–1439. [Google Scholar] [CrossRef] [PubMed]
- Barrera, J.G.; Jones, K.R.; Herman, J.P.; D’Alessio, D.A.; Woods, S.C.; Seeley, R.J. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J. Neurosci. 2011, 31, 3904–3913. [Google Scholar] [CrossRef] [PubMed]
- Sherwood, V. WNT signaling: An emerging mediator of cancer cell metabolism? Mol. Cell. Biol. 2015, 35, 2–10. [Google Scholar] [CrossRef] [PubMed]
- Holscher, C. Central effects of GLP-1: New opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 2014, 221, T31–T41. [Google Scholar] [CrossRef] [PubMed]
- Talbot, K.; Wang, H.Y. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer’s disease. Alzheimers Dement. 2014, 10, S12–S25. [Google Scholar] [CrossRef] [PubMed]
- Peng, S.; Eidelberg, D.; Ma, Y. Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson’s disease. Neurosci. Bull. 2014, 30, 823–837. [Google Scholar] [CrossRef] [PubMed]
- Berti, V.; Mosconi, L.; Pupi, A. Brain: Normal variations and benign findings in fluorodeoxyglucose-PET/computed tomography imaging. PET Clin. 2014, 9, 129–140. [Google Scholar] [CrossRef] [PubMed]
- Carpenter, K.L.; Jalloh, I.; Gallagher, C.N.; Grice, P.; Howe, D.J.; Mason, A.; Timofeev, I.; Helmy, A.; Murphy, M.P.; Menon, D.K.; et al. 13C-labelled microdialysis studies of cerebral metabolism in TBI patients. Eur. J. Pharm. Sci. 2014, 57, 87–97. [Google Scholar] [CrossRef] [PubMed]
- Tolppanen, A.M.; Lavikainen, P.; Solomon, A.; Kivipelto, M.; Uusitupa, M.; Soininen, H.; Hartikainen, S. History of medically treated diabetes and risk of Alzheimer disease in a nationwide case-control study. Diabetes Care 2013, 36, 2015–2019. [Google Scholar] [CrossRef] [PubMed]
- Biessels, G.J.; Strachan, M.W.; Visseren, F.L.; Kappelle, L.J.; Whitmer, R.A. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: Towards targeted interventions. Lancet Diabetes Endocrinol. 2014, 2, 246–255. [Google Scholar] [CrossRef]
- Butterfield, D.A.; Di Domenico, F.; Barone, E. Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain. Biochim. Biophys. Acta 2014, 1842, 1693–1706. [Google Scholar] [CrossRef] [PubMed]
- Bedse, G.; Di Domenico, F.; Serviddio, G.; Cassano, T. Aberrant insulin signaling in Alzheimer’s disease: Current knowledge. Front. Neurosci. 2015, 9, 204. [Google Scholar] [CrossRef] [PubMed]
- Devaskar, S.U.; Giddings, S.J.; Rajakumar, P.A.; Carnaghi, L.R.; Menon, R.K.; Zahm, D.S. Insulin gene expression and insulin synthesis in mammalian neuronal cells. J. Biol. Chem. 1994, 269, 8445–8454. [Google Scholar] [PubMed]
- Kuwabara, T.; Kagalwala, M.N.; Onuma, Y.; Ito, Y.; Warashina, M.; Terashima, K.; Sanosaka, T.; Nakashima, K.; Gage, F.H.; Asashima, M. Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb. EMBO Mol. Med. 2011, 3, 742–754. [Google Scholar] [CrossRef] [PubMed]
- Banks, W.A.; Owen, J.B.; Erickson, M.A. Insulin in the brain: There and back again. Pharm. Ther. 2012, 136, 82–93. [Google Scholar] [CrossRef] [PubMed]
- Le Roith, D.; Hendricks, S.A.; Lesniak, M.A.; Rishi, S.; Becker, K.L.; Havrankova, J.; Rosenzweig, J.L.; Brownstein, M.J.; Roth, J. Insulin in brain and other extrapancreatic tissues of vertebrates and nonvertebrates. Adv. Metab. Disord. 1983, 10, 303–340. [Google Scholar] [PubMed]
- Kar, S.; Chabot, J.G.; Quirion, R. Quantitative autoradiographic localization of [125I] insulin-like growth factor I, [125I] insulin-like growth factor II, and [125I] insulin receptor binding sites in developing and adult rat brain. J. Comp. Neurol. 1993, 333, 375–397. [Google Scholar] [CrossRef] [PubMed]
- O’Kusky, J.; Ye, P. Neurodevelopmental effects of insulin-like growth factor signaling. Front. Neuroendocrinol. 2012, 33, 230–251. [Google Scholar] [CrossRef] [PubMed]
- Talbot, K.; Wang, H.Y.; Kazi, H.; Han, L.Y.; Bakshi, K.P.; Stucky, A.; Fuino, R.L.; Kawaguchi, K.R.; Samoyedny, A.J.; Wilson, R.S.; et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Investig. 2012, 122, 1316–1338. [Google Scholar] [CrossRef] [PubMed]
- Bloemer, J.; Bhattacharya, S.; Amin, R.; Suppiramaniam, V. Impaired insulin signaling and mechanisms of memory loss. Prog. Mol. Biol. Transl. Sci. 2014, 121, 413–449. [Google Scholar] [PubMed]
- Faria, J.A.; Kinote, A.; Ignacio-Souza, L.M.; de Araujo, T.M.; Razolli, D.S.; Doneda, D.L.; Paschoal, L.B.; Lellis-Santos, C.; Bertolini, G.L.; Velloso, L.A.; et al. Melatonin acts through MT1/MT2 receptors to activate hypothalamic Akt and suppress hepatic gluconeogenesis in rats. Am. J. Physiol. Endocrinol. Metab. 2013, 305, E230–E242. [Google Scholar] [CrossRef] [PubMed]
- O’Neill, C. PI3-kinase/Akt/mTOR signaling: Impaired on/off switches in aging, cognitive decline and Alzheimer’s disease. Exp. Gerontol. 2013, 48, 647–653. [Google Scholar] [CrossRef] [PubMed]
- Kullmann, S.; Heni, M.; Veit, R.; Scheffler, K.; Machann, J.; Haring, H.U.; Fritsche, A.; Preissl, H. Selective insulin resistance in homeostatic and cognitive control brain areas in overweight and obese adults. Diabetes Care 2015, 38, 1044–1050. [Google Scholar] [CrossRef] [PubMed]
- Zhu, X.; Perry, G.; Smith, M.A. Insulin signaling, diabetes mellitus and risk of Alzheimer disease. J. Alzheimer's Dis. 2005, 7, 81–84. [Google Scholar] [CrossRef]
- Stanley, S.; Wynne, K.; McGowan, B.; Bloom, S. Hormonal regulation of food intake. Physiol. Rev. 2005, 85, 1131–1158. [Google Scholar] [CrossRef] [PubMed]
- Baggio, L.L.; Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132, 2131–2157. [Google Scholar] [CrossRef] [PubMed]
- Varndell, I.M.; Bishop, A.E.; Sikri, K.L.; Uttenthal, L.O.; Bloom, S.R.; Polak, J.M. Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. J. Histochem. Cytochem. 1985, 33, 1080–1086. [Google Scholar] [CrossRef] [PubMed]
- Holst, J.J.; Burcelin, R.; Nathanson, E. Neuroprotective properties of GLP-1: Theoretical and practical applications. Curr. Med. Res. Opin. 2011, 27, 547–558. [Google Scholar] [CrossRef] [PubMed]
- Cork, S.C.; Richards, J.E.; Holt, M.K.; Gribble, F.M.; Reimann, F.; Trapp, S. Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol. Metab. 2015, 4, 718–731. [Google Scholar] [CrossRef] [PubMed]
- Abbas, T.; Faivre, E.; Holscher, C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer’s disease. Behav. Brain Res. 2009, 205, 265–271. [Google Scholar] [CrossRef] [PubMed]
- Hamilton, A.; Patterson, S.; Porter, D.; Gault, V.A.; Holscher, C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res. 2011, 89, 481–489. [Google Scholar] [CrossRef] [PubMed]
- McClean, P.L.; Parthsarathy, V.; Faivre, E.; Holscher, C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J. Neurosci. 2011, 31, 6587–6594. [Google Scholar] [CrossRef] [PubMed]
- Hunter, K.; Holscher, C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012, 13, 33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hayes, M.R.; De Jonghe, B.C.; Kanoski, S.E. Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiol. Behav. 2010, 100, 503–510. [Google Scholar] [CrossRef] [PubMed]
- Williams, D.L.; Baskin, D.G.; Schwartz, M.W. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006, 55, 3387–3393. [Google Scholar] [CrossRef] [PubMed]
- Larsen, P.J.; Tang-Christensen, M.; Holst, J.J.; Orskov, C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997, 77, 257–270. [Google Scholar] [CrossRef]
- Vrang, N.; Larsen, P.J. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides. Prog. Neurobiol. 2010, 92, 442–462. [Google Scholar] [CrossRef] [PubMed]
- Llewellyn-Smith, I.J.; Reimann, F.; Gribble, F.M.; Trapp, S. Preproglucagon neurons project widely to autonomic control areas in the mouse brain. Neuroscience 2011, 180, 111–121. [Google Scholar] [CrossRef] [PubMed]
- Lovshin, J.A.; Drucker, D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009, 5, 262–269. [Google Scholar] [CrossRef] [PubMed]
- Vella, A.; Shah, P.; Reed, A.S.; Adkins, A.S.; Basu, R.; Rizza, R.A. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 2002, 45, 1410–1415. [Google Scholar] [PubMed]
- Oka, J.I.; Goto, N.; Kameyama, T. Glucagon-like peptide-1 modulates neuronal activity in the rat’s hippocampus. Neuroreport 1999, 10, 1643–1646. [Google Scholar] [CrossRef] [PubMed]
- Isacson, R.; Nielsen, E.; Dannaeus, K.; Bertilsson, G.; Patrone, C.; Zachrisson, O.; Wikstrom, L. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharm. 2011, 650, 249–255. [Google Scholar] [CrossRef] [PubMed]
- McClean, P.L.; Holscher, C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology 2014, 76, 57–67. [Google Scholar] [CrossRef] [PubMed]
- Hayes, M.R. Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects. Physiol. Behav. 2012, 106, 413–416. [Google Scholar] [CrossRef] [PubMed]
- Salcedo, I.; Tweedie, D.; Li, Y.; Greig, N.H. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: An emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br. J. Pharm. 2012, 166, 1586–1599. [Google Scholar] [CrossRef] [PubMed]
- Parthsarathy, V.; Holscher, C. Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PLoS ONE 2013, 8, e58784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Craft, S.; Baker, L.D.; Montine, T.J.; Minoshima, S.; Watson, G.S.; Claxton, A.; Arbuckle, M.; Callaghan, M.; Tsai, E.; Plymate, S.R.; et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch. Neurol. 2012, 69, 29–38. [Google Scholar] [CrossRef] [PubMed]
- McClean, P.L.; Gault, V.A.; Harriott, P.; Holscher, C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer’s disease. Eur. J. Pharm. 2010, 630, 158–162. [Google Scholar] [CrossRef] [PubMed]
- Darsalia, V.; Hua, S.; Larsson, M.; Mallard, C.; Nathanson, D.; Nystrom, T.; Sjoholm, A.; Johansson, M.E.; Patrone, C. Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization. PLoS ONE 2014, 9, e103114. [Google Scholar] [CrossRef] [PubMed]
- Adamska, E.; Ostrowska, L.; Gorska, M.; Kretowski, A. The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes. Przeglad Gastroenterol. 2014, 9, 69–76. [Google Scholar] [CrossRef] [PubMed]
- Ravassa, S.; Beaumont, J.; Huerta, A.; Barba, J.; Coma-Canella, I.; Gonzalez, A.; Lopez, B.; Diez, J. Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: A pilot study. Free Radic. Biol. Med. 2015, 81, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Toft-Nielsen, M.B.; Damholt, M.B.; Madsbad, S.; Hilsted, L.M.; Hughes, T.E.; Michelsen, B.K.; Holst, J.J. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2001, 86, 3717–3723. [Google Scholar] [CrossRef] [PubMed]
- Vilsboll, T.; Krarup, T.; Deacon, C.F.; Madsbad, S.; Holst, J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50, 609–613. [Google Scholar] [CrossRef] [PubMed]
- Candeias, E.; Sebastiao, I.; Cardoso, S.; Carvalho, C.; Santos, M.S.; Oliveira, C.R.; Moreira, P.I.; Duarte, A.I. Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats. Mol. Neurobiol. 2017. [Google Scholar] [CrossRef] [PubMed]
- Emsley, J.G.; Mitchell, B.D.; Kempermann, G.; Macklis, J.D. Adult neurogenesis and repair of the adult CNS with neural progenitors, precursors, and stem cells. Prog. Neurobiol. 2005, 75, 321–341. [Google Scholar] [CrossRef] [PubMed]
- Hamilton, A.; Holscher, C. The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer’s disease. Brain Res. 2012, 1449, 83–93. [Google Scholar] [CrossRef] [PubMed]
- Cameron, H.A.; McKay, R.D. Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus. J. Comp. Neurol. 2001, 435, 406–417. [Google Scholar] [CrossRef] [PubMed]
- Abrous, D.N.; Koehl, M.; Le Moal, M. Adult neurogenesis: From precursors to network and physiology. Physiol. Rev. 2005, 85, 523–569. [Google Scholar] [CrossRef] [PubMed]
- Bruel-Jungerman, E.; Davis, S.; Rampon, C.; Laroche, S. Long-term potentiation enhances neurogenesis in the adult dentate gyrus. J. Neurosci. 2006, 26, 5888–5893. [Google Scholar] [CrossRef] [PubMed]
- Van Praag, H.; Shubert, T.; Zhao, C.; Gage, F.H. Exercise enhances learning and hippocampal neurogenesis in aged mice. J. Neurosci. 2005, 25, 8680–8685. [Google Scholar] [CrossRef] [PubMed]
- Harkavyi, A.; Abuirmeileh, A.; Lever, R.; Kingsbury, A.E.; Biggs, C.S.; Whitton, P.S. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease. J. Neuroinflamm. 2008, 5, 19. [Google Scholar] [CrossRef] [PubMed]
- Faure, A.; Verret, L.; Bozon, B.; El Tayara, N.E.T.; Ly, M.; Kober, F.; Dhenain, M.; Rampon, C.; Delatour, B. Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer’s disease. Neurobiol. Aging 2011, 32, 407–418. [Google Scholar] [CrossRef] [PubMed]
- Bertilsson, G.; Patrone, C.; Zachrisson, O.; Andersson, A.; Dannaeus, K.; Heidrich, J.; Kortesmaa, J.; Mercer, A.; Nielsen, E.; Ronnholm, H.; et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson’s disease. J. Neurosci. Res. 2008, 86, 326–338. [Google Scholar] [CrossRef] [PubMed]
- Drucker, D.J. Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol. 2003, 17, 161–171. [Google Scholar] [CrossRef] [PubMed]
- During, M.J.; Cao, L.; Zuzga, D.S.; Francis, J.S.; Fitzsimons, H.L.; Jiao, X.; Bland, R.J.; Klugmann, M.; Banks, W.A.; Drucker, D.J.; et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 2003, 9, 1173–1179. [Google Scholar] [CrossRef] [PubMed]
- Raber, J.; Rola, R.; LeFevour, A.; Morhardt, D.; Curley, J.; Mizumatsu, S.; VandenBerg, S.R.; Fike, J.R. Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiat. Res. 2004, 162, 39–47. [Google Scholar] [CrossRef] [PubMed]
- Snyder, J.S.; Hong, N.S.; McDonald, R.J.; Wojtowicz, J.M. A role for adult neurogenesis in spatial long-term memory. Neuroscience 2005, 130, 843–852. [Google Scholar] [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bae, C.S.; Song, J. The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain. Int. J. Mol. Sci. 2017, 18, 2493. https://doi.org/10.3390/ijms18112493
Bae CS, Song J. The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain. International Journal of Molecular Sciences. 2017; 18(11):2493. https://doi.org/10.3390/ijms18112493
Chicago/Turabian StyleBae, Choon Sang, and Juhyun Song. 2017. "The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain" International Journal of Molecular Sciences 18, no. 11: 2493. https://doi.org/10.3390/ijms18112493